首页> 生物试剂> 抗体和免疫分析> ELISA> Ocaratuzumab ELISA Kit,96T,DY257078-96T,Abinscience

Ocaratuzumab ELISA Kit,96T,DY257078-96T,Abinscience

销售价: ¥ 6756.00 / 件
在线询价
优    惠: 请询价
订货号 0BC4810
品牌型号 Abinscience DY257078-96T
库存 有库存
最小订货量 1件
联系我们
  • 400-920-3909
AbinscienceELISA其它型号产品
  • 商品介绍
  • 规格参数
  • 包装参数
技术参数 Specifications
Stability and StorageThe stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Detection methodColorimetric
Sample typePlasma, Serum
Assay typeQuantitative
Sensitivity0.156 μg/ml
Range0.31-5 μg/mL
Recovery80-120%
BackgroundOcaratuzumab, previously known as AME-133v, is a humanized IgG1 type monoclonal antibody targeted at CD20 antigen, which is expressed on B-lymphocytes. Ocaratuzumab is a novel Fc-engineered monoclonal antibody designed by Applied Molecular Evolution in an attempt to induce effective antibody-dependent cell-mediated cytotoxicity (ADCC) at very low concentrations that may facilitate sub-cutaneous dosing. Libraries of antibody Fab fragment regions were generated with codon substituted variations of the antibody complementarity determining regions (CDRs) inserted into human antibody light and heavy chain germline frameworks. Then, the researchers expressed and selected mutants based on increased affinity for CD20. A variable region with increased binding activity for CD20 was selected and developed as ocaratuzumab. This drug is currently being developed by Mentrik Biotech and has been investigated in the trial for the treatment of cancer and autoimmune disorders. The pre-clinical trials of ocaratuzumab in follicular lymphoma was conducted in the United States (US) and Japan in phase I/II, and a Phase I trial was conducted in US rheumatoid arthritis patients. In addition, a phase III trial in relapsed follicular lymphoma patients is underway. Compared to rituximab, ocaratuzumab was shown to ocaratuzumab was shown to have 13 to 20 fold greater affinity for CD20 and 6 fold more potent ADCC in pre-clinical studies. The use of ocaratuzumab in other oncology and rheumatology indications has also been developed.
Alternative NamesAME-133v, LY2469298, CAS: 1169956-08-4
Shipping2-8 ℃
SpecificationsOcaratuzumab
NoteFor Research Use Only.
长度(mm)
宽度(mm)
高度(mm)
重量(kg)
猜你喜欢

在线
客服

在线客服服务时间:09:00-18:00

客服
热线

400-920-3909
客服服务热线 周一至周五(09:00-18:00)

微信
咨询

微信小程序 7X24小时在线咨询